Evidence map›Paper›PMID 35062743›Full record

ReviewVaccines2022

Effectiveness and Efficacy of Vaccine on Mutated SARS-CoV-2 Virus and Post Vaccination Surveillance: A Narrative Review.

Ihsanul Hafiz, Didi Nurhadi Illian, Okpri Meila, Ahmad Rusdan Handoyo Utomo, Arida Susilowati, Ipanna Enggar Susetya, Desrita Desrita, Gontar Alamsyah Siregar, Mohammad Basyuni

Open access · goldAbstract readReview
In one paragraph

Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ihsanul HafizDepartment of Pharmacology, Faculty of Pharmacy and Health, Institut Kesehatan Helvetia, Medan 20124, Indonesia.ORCID 0000-0003-2888-3661
Didi Nurhadi IllianDepartment of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Syiah Kuala, Banda Aceh 23111, Indonesia.ORCID 0000-0003-3559-1106
Okpri MeilaDepartment of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Syiah Kuala, Banda Aceh 23111, Indonesia.
Ahmad Rusdan Handoyo UtomoFaculty of Medicine, Universitas YARSI, Jakarta 10510, Indonesia.
Arida SusilowatiCenter of Excellence for Mangrove, Universitas Sumatera Utara, Medan 20155, Indonesia.
Ipanna Enggar SusetyaCenter of Excellence for Mangrove, Universitas Sumatera Utara, Medan 20155, Indonesia.
Desrita DesritaCenter of Excellence for Mangrove, Universitas Sumatera Utara, Medan 20155, Indonesia.
Gontar Alamsyah SiregarCenter of Excellence for Mangrove, Universitas Sumatera Utara, Medan 20155, Indonesia.
Mohammad BasyuniCenter of Excellence for Mangrove, Universitas Sumatera Utara, Medan 20155, Indonesia.ORCID 0000-0003-1120-8571
Universitas Sumatera Utara · IDUniversitas Syiah Kuala · IDBandung Institute of Technology · IDYarsi University · ID

Funding

Ministry of Education and Culture No. 2/UN5.2.3.1/PPM/KP-WCU-I/2021
6 · The paper itself

Abstract

The ongoing COVID-19 pandemic, as a result of the SARS-CoV-2 virus, since December 2019, is a major health problem and concern worldwide. The pandemic has impacted various fields, from the social to the development of health science and technology. The virus has been mutating and thus producing several new variants, rushing research in the field of molecular biology to develop rapidly to overcome the problems that occur. Vaccine clinical studies are developing promptly with the aim of obtaining vaccines that are effective in suppressing the spread of the virus; however, the development of viral mutations raises concerns about the decreasing effectiveness of the resulting vaccine, which also results in the need for more in-depth studies. There have been 330 vaccines developed, including 136 clinical developments and 194 pre-clinical developments. The SARS-CoV-2 variant continues to evolve today, and it poses a challenge in testing the effectiveness of existing vaccines. This is a narrative review describing the emergence of the COVID-19 pandemic, development of vaccine platforms, identification of concerning mutations and virus variants in various countries of the world, and real-world monitoring of post-vaccination effectiveness and surveillance.

Indexed as

COVID-19mutated SARS-CoV-2 viruspost vaccine surveillancevaccine

Identifiers

PMID35062743
PMCPMC8777947
OpenAlexW4205238742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.